Combo Therapy Boosts Response in Hairy Cell Leukemia

(MedPage Today) -- Patients with refractory or relapsed hairy-cell leukemia (HCL) can achieve a durable complete response with a short, chemotherapy-free, non-myelotoxic regimen of vemurafenib (Zelboraf) and rituximab, a small Italian study showed...